ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

serplulimab

Also written as “HLX10”, “Serplulimab + chemotherapy (carboplatin-etoposide)” and “HLX10+chemo”.

Its studies are mostly in Small Cell Lung Carcinoma · Colorectal Neoplasms · Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms, led by 3 companies.

Drug pageSerplulimab: every studyAll 107 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 6, 201927 company-led studies, 13 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma2512 open or runningphase 3since May 6, 2019Nov 19, 2018none ahead
Guangzhou FineImmune Biotechnologyits history only11 open or runningphase 1since Mar 4, 2024Mar 4, 2024none ahead
Henlixits history only10 open or runningphase 1since Mar 11, 2018Mar 11, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Fosun Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 11 earlier studies, Nov 19, 2018 to Jul 7, 2020.

  1. Jun 9, 2019Named serplulimabINNProposed as its International Nonproprietary Name in WHO's List 121
  2. Sep 7, 2020Phase 3 study in Colorectal NeoplasmsNCT04547166 · 568 planned · China, Japan
  3. Mar 17, 2021Phase 3 study in Uterine Cervical NeoplasmsNCT04806945 · China
  4. Jul 20, 2021Phase 2 study in Squamous Non-small-cell Lung CancerNCT04976647 · 156 enrolled · China
  5. Jan 22, 2022Phase 2 study in ESCC or Esophageal Adenosquamous CarcinomaNCT05221658 · 60 planned · China
  6. Feb 16, 2022Phase 2 study in Stomach NeoplasmsNCT05246982 · 40 enrolled · China
  7. Apr 25, 2022Phase 3 study in Small Cell Lung CarcinomaNCT05353257 · 511 enrolled · United States, Austria, China and more
  8. Apr 26, 2022Phase 2 study in Small Cell Lung CarcinomaNCT05354700 · 20 enrolled · China
  9. May 23, 2022Phase 1 study in Adult Solid TumorNCT05400265 · 9 enrolled · China
  10. Jun 29, 2022Phase 1 study in Solid Tumor, AdultNCT05442996 · 30 planned
  11. Jul 6, 2022Phase 1 study in Advanced or Metastatic Solid TumorsNCT05483530 · 20 enrolled · Australia
  12. Jul 11, 2022Phase 2 study in Extensive Stage Small Cell Lung CancerNCT05468489 · 200 enrolled · United States
  13. Oct 14, 2022Phase 2 study in Colorectal Cancer MetastaticNCT05584137 · 2 enrolled · China
  14. Nov 15, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05641493 · 49 planned · China
  15. Jan 22, 2025Phase 2 study in SCLC, Extensive StageNCT06812260 · 26 enrolled · Japan

TargetBeta

PDCD1 →read by rule
“A humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 25 Fosun Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06812260SCLC, Extensive Stage · Japan2Active, not recruitingOct 22, 202626
NCT05641493Carcinoma, Non-Small-Cell Lung · China2RecruitingMar 4, 202549
NCT05584137Colorectal Cancer Metastatic · China2TerminatedDec 31, 20232
NCT05468489Extensive Stage Small Cell Lung Cancer · United States2Active, not recruitingFeb 28, 2026200
NCT05483530Advanced or Metastatic Solid Tumors · Australia1Active, not recruitingDec 202420
NCT05442996Solid Tumor, Adult1Not yet recruitingApr 22, 202430
NCT05400265Adult Solid Tumor · China1CompletedAug 31, 20239
NCT05354700Small Cell Lung Carcinoma · China2UNKNOWNMar 29, 202420
NCT05353257Small Cell Lung Carcinoma · United States, Austria, China and more3Active, not recruitingJun 30, 2026511
NCT05246982Stomach Neoplasms · China2UNKNOWNDec 20, 202340
NCT05221658ESCC or Esophageal Adenosquamous Carcinoma · China2RecruitingJun 30, 202460
NCT04976647Squamous Non-small-cell Lung Cancer · China2UNKNOWNJan 30, 2023156
NCT04806945Uterine Cervical Neoplasms · China3WithdrawnFeb 15, 20240
NCT04547166Colorectal Neoplasms · China, Japan3RecruitingSep 24, 2025568
NCT04465734Carcinoma, Hepatocellular · China3WithdrawnOct 15, 20230
NCT04301739Triple Negative Breast Neoplasms3Not yet recruitingSep 7, 2022522
NCT04150575Uterine Cervical Neoplasms · China2UNKNOWNJun 15, 202221
NCT04139135Stomach Neoplasms · China3UNKNOWNOct 2023642
NCT04063163Small Cell Lung Carcinoma · Georgia, Poland, Russia and more3CompletedMay 7, 2024585
NCT04033354Neoplasm Metastasis · United States, China, Georgia and more3Active, not recruitingDec 30, 2023537
NCT03973112Carcinoma, Hepatocellular · China2UNKNOWNJun 15, 2022123
NCT03958890Esophageal Squamous Cell Carcinoma · China3UNKNOWNApr 30, 2023489
NCT03952403Carcinoma · China3Active, not recruitingOct 1, 2023643
NCT03941574MSI-H Solid Malignant Tumor · China2RecruitingMay 30, 2024108
NCT03757936Solid Tumor · China1UNKNOWNSep 27, 201930

How it is read

Names in the registry

  • “HLX10”, 15 entries
  • “Serplulimab + chemotherapy (carboplatin-etoposide)”, 1 entry
  • “HLX10+chemo”, 1 entry
  • “Serplulimab Injection”, 1 entry
  • “HLX60 combined with HLX10”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.